Full text

Turn on search term navigation

Copyright © 2022 Felix E. de Jongh et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0/

Abstract

Objectives. Patients with early-stage HR+/HER2- N0 breast cancer may receive adjuvant chemotherapy in combination with surgery. However, chemotherapy does not always lead to improved survival and incurs high healthcare costs and increased adverse events. To support decision-making regarding adjuvant chemotherapy, genomic profile testing performed with tests such as the Oncotype DX® test can help healthcare practitioners decide whether chemotherapy provides any benefit to these patients. As such, a cost-consequence model was developed with the aim to estimate the economic impact of using different gene expression tests or no testing, in patients with node-negative early-stage breast cancer. Methods. A cost-consequence model was developed to estimate the economic impact of three different scenarios in the Dutch setting: (1) Oncotype DX® test, (2) MammaPrint®, and (3) and no genomic profile testing. The model included chemotherapy costs, administration costs, short- and long-term adverse event costs, productivity loss, genomic profiling testing costs, cost of cancer recurrence, and hospitalization costs. Results. A treatment paradigm with Oncotype DX resulted in average savings per patient of €6,768 vs. a paradigm with MammaPrint and €13,125 vs. a paradigm with no genomic testing. Furthermore, due to less patients receiving adjuvant chemotherapy through better targeting by the Oncotype DX test, fewer adverse events, sick days, practice visits, and hospitalizations were required compared to MammaPrint and no genomic profiling. Conclusions. Testing with Oncotype DX test in Dutch clinical practice in patients with early-stage breast cancer proved to be cost-saving versus MammaPrint and no genomic profiling tests. Introducing the Oncotype DX test to the Dutch setting will likely reduce the economic resources that are required.

Details

Title
Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands
Author
de Jongh, Felix E 1 ; Efe, Reva 2 ; Herrmann, Kirsten H 3 ; Spoorendonk, Jelle A 2   VIAFID ORCID Logo 

 Breast Cancer Center South Holland South, Ikazia Ziekenhuis Rotterdam, Montessoriweg 1, 3083 AN, Rotterdam, Netherlands 
 OPEN Health, Marten Meesweg 107, 3068 AV, Rotterdam, Netherlands 
 Exact Sciences Deutschland GmbH, 51103 Cologne, Erna-Scheffler-Str. 1a, Germany 
Editor
Arjun Singh
Publication year
2022
Publication date
2022
Publisher
John Wiley & Sons, Inc.
ISSN
20903170
e-ISSN
20903189
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2720251000
Copyright
Copyright © 2022 Felix E. de Jongh et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0/